RCA Research is proud to spotlight HERO, the first all-RCA Investigator-Sponsored Trial (IST), evaluating aflibercept 8mg in treatment-naïve and previously treated PDR patients. This milestone study reflects the strength of our growing research network and the power of cross-practice collaboration, with enrollment completed in just 55 days across multiple sites.
We have 40 patients enrolled across three main sites and four satellite sites in Texas:
- Austin
- Round Rock
- Newcastle
- Woodlands
- Katy
- Spurs Lane
- Schertz
HERO is currently enrolling. If you are interested in learning more about participation opportunities for your site or patients, please reach out to Sarah Weidlein for additional details.